Merck & Co Inc
NYSE: MRK
$116.99
-$0.24 (-0.2%)
Real Time Data Delayed 15 Min.
MRK Articles
Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin out part of its operations. Executing this effort may create some operational uncertainty inside of...
Published:
Merck reported fourth-quarter financial results before the markets opened on Wednesday that were essentially in line with expectations, yet shares retreated in early trading.
Published:
Merck is scheduled to release its fourth-quarter financial results before the markets open on Wednesday. Analysts are looking for year-over-year growth on the top and bottom lines.
Published:
24/7 Wall St. has put together a preview of Disney, Ford, Merck, Uber and some of the other most anticipated earnings reports that are expected this week.
Published:
The January 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Here is a review and preview of how the model for Dow Jones industrial average could point to a baseline expectation of more than 7% gains in 2020.
Published:
Ahead of election years, the cost and future of health care has become one of the top debates for better than two decades now. Most politicians say that they want to lower prescription drug costs....
Published:
Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch for in early 2020.
Published:
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to watch for going into 2020.
Published:
NewLink Genetics and Merck shares made handy gains on Friday after it was announced that the FDA has granted approval to Ervebo, the Zaire Ebola virus vaccine V920.
Published:
One theme that investors love in good times and in bad is dividend investing. One strategy that has been around for years is known as the Dogs of the Dow.
Published:
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
As of the most recently reported period, short sellers favored Apple, Microsoft and Intel above all other Dow stocks.
Published: